Summary
Chronic lymphocytic leukemia (CLL) treatment strategies have improved and changed dramatically in the last few years. Insights presented at the last American Society of Hematology meeting changed standards of care in the first-line treatment. In patients <70 years with unmutated CLL, ibrutinib is the new standard resulting in a survival benefit compared to FCR (fludarabine, cyclophosphamide and rituximab). There was no progression-free survival or overall survival benefit in the subgroup of mutated patients for ibrutinib-based regimens. A randomized trial again showed no benefit of rituximab when added to ibrutinib compared to ibrutinib alone. Moreover, several promising treatment strategies in the relapsed/refractory setting were presented. The combination of ibrutinib with venetoclax reduces tumor lysis syndrome risk and generates MRD (minimal residual disease) negativity.
References
Shanafelt TD, Wang V, Kay NE, et al. A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): a trial of the ECOG-ACRIN Cancer Research Group (E1912). Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132 (Suppl 1):LBA-4.
Woyach JA, Ruppert AS, Nyla A. Heerema NA, et al. Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132 (Suppl 1):6.
Moreno C, Greil R, Demirkan F, et al. Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1): 691.
Byrd JC, Woyach JA, Furman RR, et al. Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):692.
Sun CC, Nierman P, Ahn IE, et al. Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL). Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):4424.
Jain N, Keating MJ, Thompson PA, et al. Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL). Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):696.
Hillmen P, Rawstron A, Brock K, et al. Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):182.
Greil R, Fraser G, Leber B, et al. Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):5548.
Kater AP, Hillmen P, Eichhorst B, et al. First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):185.
Mato AR, Svoboda J, Luning Prak ET, et al. Phase I/II Study of umbralisib (TGR-1202) in combination with ublituximab (TG-1101) and pembrolizumab in patients with relapsed/refractory CLL and Richter’s Transformation. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):297.
Staber PB, Chanan-Khan AA, Munir T, et al. Two-Cohort Phase II Study in R/R CLL (COSMOS): First Preliminary Safety and Efficacy Results of Anti-CD19 MOR208 Treatment in Combination with Venetoclax in Patients Who Discontinued Prior BTK Inhibitor Therapy. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):4433.
Siddiqi T, Soumerai JD, Wierda WG, et al. Rapid MRD-negative responses in patients with relapsed/refractory CLL treated with Liso-Cel, a CD19-directed CAR T-cell product: preliminary results from Transcend CLL 004, a phase 1/2 study including patients with high-risk disease previously treated with ibrutinib. Presented at the 2018 ASH Annual Meeting, December 4, 2018; San Diego, CA. Blood 2018;132(Suppl 1):300.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
D. Heintel received honoraria and travel support from AbbVie, Celgene, Janssen, Gilead, MSD, Roche, Takeda.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Heintel, D. Highlights on chronic lymphocytic leukemia presented at the 2018 American Society of Hematology Meeting. memo 12, 200–202 (2019). https://doi.org/10.1007/s12254-019-00521-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-019-00521-y